跳至主要内容
临床试验/IRCT20220422054617N1
IRCT20220422054617N1招募中3 期

evaluation of the effect of rivaroxaban in comparison with warfarin in preventing deep vein thrombosis in patients with nephrotic syndrom

Shiraz University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Newly diagnosed nephrotic syndrome
  • Albumin less than 2.5 in a patient with MGN
  • Albumin less than 2 in other cases of nephrotic syndrome
  • The age of the patient is between 18 and 60 years
  • The patient's bleeding risk according to HAS-BLED criteria is low to moderate risk
  • GFR greater than 60

排除标准

  • coagulation disorders
  • active cancer
  • taking aspirin
  • taking plavix

研究者

相似试验